FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:2156-2157 November 16, 2006 Number 20 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by de Nijs, R. N.J.

To the Editor: De Nijs et al. (Aug. 17 issue)¹ report that alendronate was more effective in the prevention of glucocorticoid-induced bone loss than was alfacalcidol. This is a well-done study, but we are concerned that the authors did not address the fact that glucocorticoid therapy can have rapid effects on bone. It has been reported that the negative influence of glucocorticoid agents may be most pronounced in the first months of therapy.² In patients with Crohn's disease, significant bone loss at the hip was detected after 2 months of such treatment.³ Therefore, because the study by de Nijs et . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.